For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma reported a revenue of €57.8 million in Q3 2024, driven by product launches and ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma has released its unaudited financial results for the period ending September 30, ...

Insight into Druckenmiller's Latest 13F Filings and Portfolio Adjustments. Stanley Druckenmiller (Trades, Portfolio), the ...

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

COPENHAGEN - Ascendis Pharma A/S (NASDAQ:ASND) has reported encouraging outcomes from its ongoing Phase 1/2 IL-Believe Trial, evaluating TransCon IL-2 β/γ therapy for ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

European equities traded in the US as American depositary receipts were moving higher late Monday morning, rising 0.35% to 1,339.76 on the S&P Europe Select ADR Index. From continental Europe, the ...

GET MORE AI-GENERATED SIGNALS: November 10, 2024, 17:44 pm ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...